Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

The aim of this study was to determine the effects of micronized fenofibrate (160 mg/daily)
on:

1. Fasting and postprandial lipids and lipoproteins after a standarized test meal.

2. Fasting and postprandial oxidized fatty acids and oxidized low density lipoprotein
after a standarized test meal.

3. Fasting and postprandial inflammatory mediators after a standarized test meal.

4. Fasting and postprandial lipopolysaccharide-stimulated cytokine production after a
standarized test meal.

5. Fasting and postprandial markers of hemostasis, fibrinolysis and blood viscosity after
a standarized test meal.

Inclusion Criteria:

1. males and postmenopausal females 18 years of age with fasting triglycerides greater
than or equal to 1.7 mmol/L and <6.9 mmol/L

2. two or more of the following Adult Treatment Panel III (1) criteria of the metabolic
syndrome: abdominal obesity (waist circumference >89 cm in females and >102 cm in
males); low high-density lipoprotein cholesterol (HDL-C) (<1.3 mmol/L in women and
<1.0 mmol/L in men); hypertension (systolic blood pressure >130 or diastolic blood
pressure >85 mm Hg) or current drug therapy for hypertension; and impaired fasting
glucose (between 6.1 mmol/L and 7.0 mmol/L).

Exclusion Criteria:

1. included types 1 or 2 diabetes

2. Body mass index >40 kg/m2

3. Use of lipid-lowering therapies

4. Oral hypoglycemic therapies

5. Insulin

6. Aspirin >81 mg daily

7. Regular use of non-steroidal anti-inflammatory agents or cyclooxygenase-2 inhibitors,
corticosteroids (oral and inhaled), anti-oxidants (including multivitamins), herbal
or fiber supplements recent changes in type or formulation of hormone replacement
therapy (in the last 6 months)

8. Alcohol intake >3 drinks per day

9. Untreated hypothyroidism or recent change (within 2 months) of thyroid replacement
therapy

10. Cigarette smoking (current or within the last 6 months)